Related Experiment Video
Updated: May 12, 2026
26:48
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Myasthenia gravis complicated with autoimmune encephalitis: a review
1Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Frontiers in Neurology
|May 11, 2026
Summary
Myasthenia gravis (MG) and autoimmune encephalitis, both antibody-mediated disorders, can co-exist, presenting diagnostic and therapeutic challenges. Updated guidelines and targeted therapies are crucial for managing this complex comorbidity.
Area of Science:
- Neurology
- Immunology
- Autoimmune Disorders
Background:
- Myasthenia gravis (MG) and autoimmune encephalitis are distinct yet related antibody-mediated neurological disorders.
- Co-occurrence of MG and autoimmune encephalitis poses significant diagnostic and therapeutic challenges.
- Understanding shared mechanisms and risk factors is vital for managing these conditions.
Purpose of the Study:
- To provide updated information on myasthenia gravis (MG) complicated by autoimmune encephalitis.
- To review the diagnostic and therapeutic challenges associated with co-existing MG and autoimmune encephalitis.
- To explore the overlapping pathogenesis and treatment strategies for these antibody-mediated disorders.
Main Methods:
- A comprehensive literature search was conducted.
- Keywords included "myasthenia gravis," "autoimmune encephalitis," and specific associated antibodies.
- Data synthesis focused on epidemiological findings and case reports.
Main Results:
- Epidemiological data and case reports indicate an increased risk of autoimmune encephalitis in patients with MG.
- Antibody targets, clinical presentations, treatment choices, and prognoses vary based on the specific antibody profile.
- Standard immunosuppressive treatments for MG are recommended, with options like corticosteroids, IVIg, plasma exchange, rituximab, and FcRn-blockers for autoimmune encephalitis.
Conclusions:
- Myasthenia gravis and autoimmune encephalitis share overlapping pathogenesis and respond to similar therapeutic agents.
- Managing this comorbidity often requires high-dose, combination immunosuppressive therapy.
- Emerging targeted therapies for MG may also hold promise for treating autoimmune encephalitis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:19Encephalitis l: Introduction
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
01:26Encephalitis ll: Pathophysiology
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...